Drug Pipeline

BXCL501 60 Micrograms Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
2
Recruiting
3
Top Sponsors
Active Studies by Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06943404 BXCL501 After Stress to Increase Recovery Success Acute Stress Reaction Recruiting
Phase 1/2
NCT05712707 Sublingual Dexmedetomidine for Treating Opioid Withdrawal Opioid Use Disorder Active, Not Recruiting
Phase 1
NCT05025605 Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric… Schizophrenia Recruiting
Sponsors Running BXCL501 60 Micrograms Trials
BioXcel Therapeutics Inc (1) New York State Psychiatric Institute (1) University of North Carolina, Chapel Hill (1)
Disease Areas
Bipolar Disorder (1) Schizophrenia (1) PTSD (1)
Get alerts when BXCL501 60 Micrograms trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free